secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001935979-25-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven reports $489M cash; FDA accepts troriluzole NDA with Priority Review for SCA
--------------------------------------------------------------------------------

- Cash & securities totaled $489M as of Dec 31, 2024; R&D expenses Q4 2024 were $167.5M (vs $134.8M Q4 2023).
- FDA accepted troriluzole NDA for spinocerebellar ataxia with Priority Review; PDUFA date in 3Q 2025.
- BHV-1300 (IgG degrader) achieved up to 84% reduction of total IgG in Phase 1; Phase 2 in Graves' disease expected mid-2025.
- Next-gen TRAP degraders BHV-1400 (IgAN) and BHV-1600 (PPCM) advanced; Phase 1 completion expected 1H 2025.
- Multiple pipeline milestones expected: BHV-7000 MDD topline 2H 2025, BHV-8000 Parkinson's study initiation 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/0001935979-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597925000016/bhvn-20250303.htm
  HTML page:      https://secwatch.observer/filing/0001935979-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer